CA2002859A1 - Methode de traitement d'affections epitheliales - Google Patents

Methode de traitement d'affections epitheliales

Info

Publication number
CA2002859A1
CA2002859A1 CA2002859A CA2002859A CA2002859A1 CA 2002859 A1 CA2002859 A1 CA 2002859A1 CA 2002859 A CA2002859 A CA 2002859A CA 2002859 A CA2002859 A CA 2002859A CA 2002859 A1 CA2002859 A1 CA 2002859A1
Authority
CA
Canada
Prior art keywords
compounds
epithelial disorders
treating epithelial
warm
see
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2002859A
Other languages
English (en)
Other versions
CA2002859C (fr
Inventor
Jean P. F. Van Wauwe
Alfons H. M. Raeymaekers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2002859A1 publication Critical patent/CA2002859A1/fr
Application granted granted Critical
Publication of CA2002859C publication Critical patent/CA2002859C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/496—Triazoles or their condensed derivatives, e.g. benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002002859A 1988-11-29 1989-11-14 Methode de traitement d'affections epitheliales Expired - Lifetime CA2002859C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27715288A 1988-11-29 1988-11-29
US277,152 1988-11-29

Publications (2)

Publication Number Publication Date
CA2002859A1 true CA2002859A1 (fr) 1990-05-29
CA2002859C CA2002859C (fr) 1998-12-29

Family

ID=23059616

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002002859A Expired - Lifetime CA2002859C (fr) 1988-11-29 1989-11-14 Methode de traitement d'affections epitheliales

Country Status (16)

Country Link
EP (2) EP0609963B1 (fr)
JP (2) JP2752200B2 (fr)
AT (2) ATE112681T1 (fr)
AU (2) AU623454B2 (fr)
CA (1) CA2002859C (fr)
CY (1) CY1867A (fr)
DE (2) DE68918809T2 (fr)
DK (1) DK175793B1 (fr)
ES (2) ES2173902T3 (fr)
HK (1) HK114895A (fr)
IE (1) IE63877B1 (fr)
IL (1) IL92487A (fr)
NZ (1) NZ231405A (fr)
PT (1) PT92449B (fr)
SG (1) SG50466A1 (fr)
ZA (1) ZA899074B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002859C (fr) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Methode de traitement d'affections epitheliales
JPH08502990A (ja) * 1992-11-10 1996-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 鏡像体的に純粋な６−［（４−クロロフェニル）（１ｈ−１，２，４−トリアゾール−１−イル）メチル−１−メチル−１ｈ−ベンゾトリアゾールの製造方法
JPH09508915A (ja) * 1994-02-18 1997-09-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フェンノートシヤツプ 鏡像異性体的に純粋な（−）−リアロゾール
NZ279227A (en) * 1994-02-18 1997-11-24 Janssen Pharmaceutica Nv Dextrorotatory (+)-5-[3-chlorophenyl]-1h-imidazol-1-ylmethyl]-1h-benzimidazole derivatives (liarozole)
EP0800391A1 (fr) * 1994-12-28 1997-10-15 Janssen Pharmaceutica N.V. Benzimidazoles utilises comme inhibiteurs du metabolisme du calcitriol
TW316902B (fr) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
WO1997006788A1 (fr) * 1995-08-14 1997-02-27 Janssen Pharmaceutica N.V. Administration trans-cutanee de vorozole
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
BR9710002A (pt) 1996-06-27 1999-08-10 Janssen Pharmaceutica Nv N-[4-(heteroarilmetil)fenil]-heteroarilaminas
JPH10220909A (ja) 1996-12-03 1998-08-21 Komatsu Ltd 流体温度制御装置
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
HUP0100860A3 (en) * 1997-12-11 2003-03-28 Janssen Pharmaceutica Nv Retinoic acid mimetic anilides, process for their preparation and pharmaceutical compositions containing them
CA2335435A1 (fr) * 1998-06-16 1999-12-23 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Derives d'imidazolyle
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
CA2370633A1 (fr) * 1999-04-29 2000-11-09 Avon Products, Inc. Methode pour ameliorer l'aspect esthetique de l'epithelium
EP1420015A1 (fr) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Dérivés de l'imidazole
FR2815857B1 (fr) * 2000-10-30 2003-02-14 Oreal Composition, notamment cosmetique, renfermant un retinoide et une silicone benzotriazole
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2504448C (fr) * 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
SG181947A1 (en) 2009-12-30 2012-07-30 Arqule Inc Substituted imidazopyridinyl-aminopyridine compounds
CA2837727C (fr) 2011-06-24 2019-12-03 Arqule, Inc. Composes d'imidazopyridinyle-aminopyridine substitues
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
CA2002859C (fr) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Methode de traitement d'affections epitheliales

Also Published As

Publication number Publication date
ES2173902T3 (es) 2002-11-01
ES2065369T3 (es) 1995-02-16
DK599589A (da) 1990-05-30
IL92487A0 (en) 1990-08-31
CY1867A (en) 1996-04-05
AU4564889A (en) 1990-06-07
IE950033L (en) 1990-05-29
HK114895A (en) 1995-07-21
DE68929377D1 (de) 2002-04-11
EP0609963A1 (fr) 1994-08-10
EP0371559B1 (fr) 1994-10-12
DE68929377T2 (de) 2002-10-31
AU623454B2 (en) 1992-05-14
PT92449B (pt) 1995-07-18
EP0609963B1 (fr) 2002-03-06
CA2002859C (fr) 1998-12-29
IL92487A (en) 1994-12-29
ATE213941T1 (de) 2002-03-15
AU1071692A (en) 1992-03-19
JPH0320273A (ja) 1991-01-29
DK599589D0 (da) 1989-11-28
IE63877B1 (en) 1995-06-14
ZA899074B (en) 1991-07-31
SG50466A1 (en) 1998-07-20
DE68918809D1 (de) 1994-11-17
JP2912596B2 (ja) 1999-06-28
EP0371559A2 (fr) 1990-06-06
DK175793B1 (da) 2005-02-21
EP0371559A3 (fr) 1992-04-08
JPH1095782A (ja) 1998-04-14
JP2752200B2 (ja) 1998-05-18
AU630579B2 (en) 1992-10-29
PT92449A (pt) 1990-05-31
IE893781L (en) 1990-05-29
NZ231405A (en) 1991-08-27
DE68918809T2 (de) 1995-03-23
ATE112681T1 (de) 1994-10-15

Similar Documents

Publication Publication Date Title
CA2002859A1 (fr) Methode de traitement d'affections epitheliales
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
EP0303915A3 (en) Retinoids for the treatment of skin damaged by light
DE3568272D1 (en) 4-vinylbenzoic-acid derivatives, their preparation and their use as therapeutical compositions and as ligands
AU3202595A (en) 1,2-substituted imidazolyl compounds for the treatment of inflammation
EP0313305A3 (fr) Compositions photoprotectrices contenant des agents chélatants
IE862543L (en) Pharmaceutical compositions
CA2140106A1 (fr) Methode de traitement des affections vasculaires hyperproliferatives
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
TR200000009T2 (tr) Triazol bileşikleri ve bunların dopamin-D3-ligandları olarak kullanımları.
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
CA2015838A1 (fr) Methode de traitement topique de l'acne
SE9303691D0 (sv) New beverage
WO1992019617A3 (fr) Composes de dibenzoxazepine substituee, compositions pharmaceutiques et procedes d'utilisation
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
MY100900A (en) Substituted phenylsulfonyloxybenzimidazolecarbamates, processes for their preparation and their use as medicaments.
DE69311541D1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
IT8320435A0 (it) Composizione per il trattamento dell'acne.
ATE123773T1 (de) 1,3,5-triazin-2,4,6-tris- alkylaminocarbonsäureaminoester, diese enthaltende biozide mittel sowie verfahren zu ihrer herstellung.
AU640647B2 (en) 3-butenamide derivatives
FR2569569B1 (fr) Exerciseur destine notamment au travail du grand ecart.
IL105122A0 (en) Benzimidazole derivative for use as an anti-irritant
NO874241D0 (no) Terapeutisk aktive salter.
ES2166834T3 (es) Uso de agentes antiviricos de aminopurina para el tratamiento y profilaxis de infecciones latentes de herpesvirus.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry